Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2005

View Archived Issues

MF-101: a safer alternative for hormonal therapy

In vivo studies confirm the anti-HSV activity of a cream formulation of resveratrol

Anti-HBV activity of ellagic acid

Vestipitant shows anxiolytic-like profile in rodent and primate behavioral models

DPI-221 shows potential as an agent for overactive bladder and urinary incontinence

Scientists describe advantages of using two antibodies in PAGRIT

Aripiprazole reported effective in preventing relapse of patients with bipolar disorder

Scientists find link between novel locus and left main coronary artery disease risk

Phase II study discontinued for vicriviroc in treatment-naive HIV patients

Cellegy completes enrollment in phase III HIV prevention study of Savvy

Approval of muraglitazar may require new trials

Enrollment begins in phase I Chemophase study

Biolex to create commercial line for Kringle's NK4 protein

Update on ongoing Avian flu research

Positive phase III results for GSK drug from Flamel collaboration

Dacogen under review in U.S. and Europe for MDS

Positive phase I findings for Fentanyl Taifun

Chromos Molecular Systems to acquire Targeted Molecules

Accelerated approval for Arranon

FDA extends Exubera review period

Erbitux sBLA accepted for filing, granted priority review

Cerepro MAA accepted for review

Schering-Plough seeks Japanese approval of Temodal

Escitalopram reported to improve kleptomania, PMDD and depression

MD-1100 demonstrates gastrointestinal activity in healthy volunteers

Novel antiinfective agents emerge from sanofi-aventis R&D

New therapeutic agents claimed for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...